Could a common supplement slow ALS? duke launches pilot trial

NCT ID NCT07589764

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether a daily supplement called HMB (beta-hydroxy-beta-methylbutyrate) is safe and can lower certain blood markers linked to ALS. One hundred adults with ALS will take 3 grams of HMB daily. Researchers will track changes in blood markers and functional abilities over time. The goal is to see if HMB might slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
beta-hydroxy-beta-methylbutyrate (HMB) supplement
What this could lead to
If it works, this could point toward a simple supplement to slow ALS progression and improve quality of life.
What could go wrong
This is a very early Phase 1 pilot trial with only 100 people, no placebo group, and it measures a biomarker (IGFBP7) that may not directly translate to clinical benefit. The supplement may not slow the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Duke University Medical Center

    Durham, North Carolina, 27705, United States

    Contact

    Contact Email: •••••@•••••

  • Temple University

    Philadelphia, Pennsylvania, 19122, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.